

Shixin Tao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/362603/publications.pdf>

Version: 2024-02-01

9
papers

255
citations

1163117
8
h-index

1588992
8
g-index

9
all docs

9
docs citations

9
times ranked

382
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy. <i>Oncogene</i> , 2020, 39, 1231-1245.	5.9	31
2	Glycogen synthase kinase-3 β inhibits tubular regeneration in acute kidney injury by a FoxM1-dependent mechanism. <i>FASEB Journal</i> , 2020, 34, 13597-13608.	0.5	20
3	Epithelial Vasopressin Type-2 Receptors Regulate Myofibroblasts by a YAP-CCN2-Dependent Mechanism in Polycystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1697-1710.	6.1	26
4	A cAMP and CREB-mediated feed-forward mechanism regulates GSK3 β in polycystic kidney disease. <i>Journal of Molecular Cell Biology</i> , 2016, 8, 464-476.	3.3	16
5	Glycogen synthase kinase-3 inhibition attenuates fibroblast activation and development of fibrosis following renal ischemia/reperfusion in mice. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 931-40.	2.4	50
6	Glycogen synthase kinase-3 β promotes cyst expansion in polycystic kidney disease. <i>Kidney International</i> , 2015, 87, 1164-1175.	5.2	39
7	Glycogen synthase kinase 3 β regulates urine concentrating mechanism in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, F650-F660.	2.7	26
8	Glycogen Synthase Kinase-3 Inhibition Reduces Renal Cystogenesis in Polycystic Kidney Disease. <i>FASEB Journal</i> , 2013, 27, 1115.20.	0.5	0
9	Specific deletion of glycogen synthase kinase-3 β in the renal proximal tubule protects against acute nephrotoxic injury in mice. <i>Kidney International</i> , 2012, 82, 1000-1009.	5.2	47